Assembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above Two Hundred Day Moving Average of $10.92

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.92 and traded as high as $13.90. Assembly Biosciences shares last traded at $13.41, with a volume of 11,396 shares traded.

Analysts Set New Price Targets

Several research firms recently weighed in on ASMB. StockNews.com upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Friday, April 5th. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research note on Monday, April 1st.

Assembly Biosciences Price Performance

The stock’s 50 day simple moving average is $12.93 and its two-hundred day simple moving average is $10.93.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ASMB. JPMorgan Chase & Co. boosted its stake in Assembly Biosciences by 15,633.0% in the first quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 14,695 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Assembly Biosciences during the 1st quarter valued at approximately $106,000. State Street Corp lifted its stake in shares of Assembly Biosciences by 15.7% during the 1st quarter. State Street Corp now owns 145,335 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 19,712 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Assembly Biosciences by 123.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,772 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 68,411 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Assembly Biosciences during the 1st quarter valued at approximately $27,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.